Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1534158 | 1.00 | CA1 (0.33) | CA1CA2LMNABLMPMP22 | |
| Phosphoric Acid SCHEMBL8075511 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL21977515 | 0.93 | LMNA (0.35) | LMNA | |
| Phosphoric Acid SCHEMBL21980911 | 0.92 | SLC34A1 (0.38) | — | |
| Phosphoric Acid SCHEMBL8020162 | 0.89 | — | — | |
| Phosphoric Acid SCHEMBL28128544 | 0.86 | SLC34A1 (0.41) | LMNA | |
| Phosphoric Acid SCHEMBL28816396 | 0.86 | SLC34A1 (0.41) | CA2LMNA | |
| Phosphoric Acid SCHEMBL28904932 | 0.86 | SLC34A1 (0.50) | CA2LMNA | |
| Phosphoric Acid SCHEMBL929741 | 0.86 | — | — | |
| Phosphoric Acid SCHEMBL27513925 | 0.86 | SLC34A1 (0.41) | CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933647-B | Preparation method of insulin crystal and product | 重庆宸安生物制药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-109717445-B | Sweet taste composition and preparation method and application thereof | 湖南绿蔓生物科技股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114933647-A | Preparation method of insulin crystal and product | 重庆宸安生物制药有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-111424065-B | Method for glycosylating stevioside compounds by using glycosyltransferase | 金禾益康(北京)生物科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20210352943-A1 | SWEETENING COMPOSITION AND PREPARATION METHOD AND USE THEREOF | HUNAN NUTRAMAX INC. (CN) | 2021-11-18 | — | — | US | disclosed |
| CN-113337568-A | Method for enzymatic regeneration of redox cofactors | 安尼基有限责任公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3736280-A1 | SWEETENER COMPOSITION AND PREPARATION METHOD AND USE THEREOF | Hunan Nutramax Inc. (CN) | 2020-11-11 | — | — | EP | disclosed |
| CN-111424065-A | Method for glycosylating stevioside compounds by using glycosyltransferase | 中粮营养健康研究院有限公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-2661619-B1 | Chemosensors and method for determining hydrogen sulfide | UNIV GEORGIA STATE RES FOUND (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-1218007-B1 | OPTICALLY ACTIVE ISOMERS OF KETOTIFEN AND THERAPEUTICALLY ACTIVE METABOLITES THEREOF | BRIDGE PHARMA INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7557128-B2 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090149502-A1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | ABERG A K GUNNAR | 2009-06-11 | — | — | US | disclosed |
| US-20080287498-A1 | Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen | ABERG A K GUNNAR | 2008-11-20 | — | — | US | disclosed |
| US-7371362-B2 | Catalytic wet oxidation of lactose | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070197825-A1 | Catalytic Wet Oxidation of Lactose | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2007-08-23 | — | — | US | disclosed |
| US-7226934-B1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1218007-A4 | OPTICALLY ACTIVE ISOMERS OF KETOTIFEN AND THERAPEUTICALLY ACTIVE METABOLITES THEREOF | BRIDGE PHARMA INC (US) | 2003-04-09 | — | — | EP | disclosed |
| CN-1391475-A | Optical isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA INC (US) | 2003-01-15 | — | — | CN | disclosed |
| EP-1218007-A1 | OPTICALLY ACTIVE ISOMERS OF KETOTIFEN AND THERAPEUTICALLY ACTIVE METABOLITES THEREOF | Bridge Pharma, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001019367-A1 | OPTICALLY ACTIVE ISOMERS OF KETOTIFEN AND THERAPEUTICALLY ACTIVE METABOLITES THEREOF | BRIDGE PHARMA, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287498-A1 | Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen | OPRK1, HRH2, HRH1 | CA1 3313/4885CA2 3630/4885LMNA 4194/4885 |
| US-20090149502-A1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | OPRK1, HRH1, HRH2 | CA1 2982/4885CA2 3646/4885LMNA 4200/4885 |
| US-20070197825-A1 | Catalytic Wet Oxidation of Lactose | LPO, MGAM, LCT | CA1 13/4885CA2 27/4885LMNA 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.